AEON Biopharma and Priveterra Announce Arrangement of Up to $125 Million of Financing in Connection with Proposed Business Combination

AEON Biopharma and Priveterra have announced the arrangement of up to $125 million in financing for their proposed business combination. The funding includes $50 million from existing and new AEON investors, as well as cash from Priveterra's trust account. This funding will allow AEON to continue its development of a botulinum toxin complex for the treatment of medical conditions, including migr..